Form 4 Filing for Centessa Pharmaceuticals plc

This Form 4 filing details transactions by Gregory M. Weinhoff, Chief Business Officer of Centessa Pharmaceuticals plc, on June 24, 2026. The transactions are related to the acquisition of the company by Eli Lilly and Company through a scheme of arrangement. Weinhoff disposed of 65,925 ordinary shares. Additionally, several share options were cancelled and converted into the right to receive cash and contingent value rights (CVRs). These options, held directly and indirectly, included various exercise prices and expiration dates. The total number of shares underlying these options amounted to 1,178,323. The cash consideration for ordinary shares and underlying securities was $38.00 per share, with potential additional payments of up to $9.00 per share via CVRs, contingent on specified milestones. All transactions resulted in a post-transaction share count of zero for Weinhoff.